The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors

The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands ( www.guidetopharmacology.org ), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full . G protein‐coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand‐gated ion channels, voltage‐gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The Concise Guide is published in landscape format in order to facilitate comparison of related targets. It is a condensed version of material contemporary to late 2015, which is presented in greater detail and constantly updated on the website www.guidetopharmacology.org , superseding data presented in the previous Guides to Receptors & Channels and the Concise Guide to PHARMACOLOGY 2013/14. It is produced in conjunction with NC‐IUPHAR and provides the official IUPHAR classification and nomenclature for human drug targets, where appropriate. It consolidates information previously curated and displayed separately in IUPHAR‐DB and GRAC and provides a permanent, citable, point‐in‐time record that will survive database updates.

[1]  S. Liberles Trace amine-associated receptors: ligands, neural circuits, and behaviors , 2015, Current Opinion in Neurobiology.

[2]  A. Pioszak,et al.  Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor , 2015, Molecular cell.

[3]  Y. Yung,et al.  Lysophosphatidic acid signalling in development , 2015, Development.

[4]  Richard J. Edwards,et al.  Metabotropic Glutamate Receptors , 2015, The Journal of Biological Chemistry.

[5]  J. Chun,et al.  LPA signaling initiates schizophrenia-like brain and behavioral changes in a mouse model of prenatal brain hemorrhage , 2015, Translational Psychiatry.

[6]  Y. Yung,et al.  Lysophosphatidic Acid Signaling in the Nervous System , 2015, Neuron.

[7]  A. Russo Calcitonin gene-related peptide (CGRP): a new target for migraine. , 2015, Annual review of pharmacology and toxicology.

[8]  L. Devi,et al.  Challenges for opioid receptor nomenclature: IUPHAR Review 9 , 2015, British journal of pharmacology.

[9]  R. Glen,et al.  Abstract 15352: ELABELA/Toddler, a Critical Regulator of Cardiac Development, is Expressed in the Human Cardiovascular System and Binds the Apelin Receptor , 2014 .

[10]  J. Furness,et al.  Novel and Conventional Receptors for Ghrelin, Desacyl-Ghrelin, and Pharmacologically Related Compounds , 2014, Pharmacological Reviews.

[11]  D. Lambert,et al.  Functional plasticity of the N/OFQ‐NOP receptor system determines analgesic properties of NOP receptor agonists , 2014, British journal of pharmacology.

[12]  S. Spiegel,et al.  Lysophospholipid receptor nomenclature review: IUPHAR Review 8 , 2014, British journal of pharmacology.

[13]  Y. Yung,et al.  LPA receptor signaling: pharmacology, physiology, and pathophysiology , 2014, Journal of Lipid Research.

[14]  Jay Halai Behaviour management: Creating the right climate for learning , 2014 .

[15]  A. Lehmann,et al.  Fine‐tuning somatostatin receptor signalling by agonist‐selective phosphorylation and dephosphorylation: IUPHAR Review 5 , 2014, British journal of pharmacology.

[16]  R. Mechoulam,et al.  The endocannabinoid system and the brain. , 2013, Annual review of psychology.

[17]  M. von Zastrow,et al.  Regulation of µ-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance , 2013, Pharmacological Reviews.

[18]  R. Jensen,et al.  Bombesin-Related Peptides , 2013 .

[19]  R. Summers,et al.  Relaxin family peptides and their receptors. , 2013, Physiological reviews.

[20]  K. Ressler,et al.  Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y , 2012, Physiology & Behavior.

[21]  M. Knepper Systems biology in physiology: the vasopressin signaling network in kidney. , 2012, American journal of physiology. Cell physiology.

[22]  R. Barker,et al.  Neuropeptide Y and its role in CNS disease and repair , 2012, Experimental Neurology.

[23]  R. Landgraf,et al.  Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors , 2012, Trends in Neurosciences.

[24]  E. Butelman,et al.  κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction , 2012, Trends in Neurosciences.

[25]  A. Schober,et al.  Lysophosphatidic acid in atherosclerotic diseases , 2012, British journal of pharmacology.

[26]  Taka-aki Koshimizu,et al.  Vasopressin V1a and V1b receptors: from molecules to physiological systems. , 2012, Physiological reviews.

[27]  G. Burnstock,et al.  Purinergic Signalling and the Nervous System , 2012, Springer Berlin Heidelberg.

[28]  B. Slusher,et al.  Pharmacological mechanisms of 5-HT₃ and tachykinin NK₁ receptor antagonism to prevent chemotherapy-induced nausea and vomiting. , 2012, European journal of pharmacology.

[29]  L. Eiden,et al.  Is PACAP the Major Neurotransmitter for Stress Transduction at the Adrenomedullary Synapse? , 2012, Journal of Molecular Neuroscience.

[30]  C. Salvatore,et al.  Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine , 2012, British journal of pharmacology.

[31]  H. Vaudry,et al.  Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide: IUPHAR Review 1 , 2012, British journal of pharmacology.

[32]  J. Archbold,et al.  Calcitonin and calcitonin receptor‐like receptors: common themes with family B GPCRs? , 2012, British journal of pharmacology.

[33]  R. Quirion,et al.  The pharmacology of Adrenomedullin 2/Intermedin , 2012, British journal of pharmacology.

[34]  U. Plöckinger Medical Therapy of Acromegaly , 2012, International journal of endocrinology.

[35]  A. Tamas,et al.  Effects of pituitary adenylate cyclase activating polypeptide in the urinary system, with special emphasis on its protective effects in the kidney , 2012, Neuropeptides.

[36]  G. Guillon,et al.  Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics , 2012, Journal of neuroendocrinology.

[37]  S. Peineau,et al.  Molecular mechanisms of somatostatin receptor trafficking. , 2012, Journal of molecular endocrinology.

[38]  J. Chun,et al.  Insights into the pharmacological relevance of lysophospholipid receptors , 2012, British journal of pharmacology.

[39]  Peter Kirsch,et al.  Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine , 2011, Nature Reviews Neuroscience.

[40]  R. Hampson,et al.  Endocannabinoid tone versus constitutive activity of cannabinoid receptors , 2011, British journal of pharmacology.

[41]  Lei Zhang,et al.  The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. , 2011, Pharmacology & therapeutics.

[42]  N. Bolger,et al.  Social effects of oxytocin in humans: context and person matter , 2011, Trends in Cognitive Sciences.

[43]  F. Xu Synthesis of Telcagepant , 2011 .

[44]  R. Ivell,et al.  Relaxin family peptides in the male reproductive system--a critical appraisal. , 2011, Molecular human reproduction.

[45]  Z. Andrews The extra-hypothalamic actions of ghrelin on neuronal function , 2011, Trends in Neurosciences.

[46]  Xiuxia Liu,et al.  Prostaglandin E receptors as inflammatory therapeutic targets for atherosclerosis. , 2011, Life sciences.

[47]  S. Leeman,et al.  Neurokinin‐1 receptor: functional significance in the immune system in reference to selected infections and inflammation , 2011, Annals of the New York Academy of Sciences.

[48]  N. Rance,et al.  Neurokinin B and the hypothalamic regulation of reproduction , 2010, Brain Research.

[49]  P. Georgoulias,et al.  Current and potential roles of ghrelin in clinical practice , 2010, Journal of endocrinological investigation.

[50]  Z. Andrews,et al.  Metabolic Status Regulates Ghrelin Function on Energy Homeostasis , 2010, Neuroendocrinology.

[51]  Sarah Spiegel,et al.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature , 2010, Pharmacological Reviews.

[52]  Stuart Maudsley,et al.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders. , 2010, CNS & neurological disorders drug targets.

[53]  E. Ghigo,et al.  Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. , 2010, Journal of molecular endocrinology.

[54]  G. Kouraklis,et al.  Ghrelin: A potential therapeutic target for cancer , 2010, Regulatory Peptides.

[55]  T. Comery,et al.  SAM-531, N,N-dimethyl-3-{[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy} propan-1-amine, a novel serotonin-6 receptor antagonist with preclinical pro-cognitive efficacy , 2010, Alzheimer's & Dementia.

[56]  A. Zengin,et al.  Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat , 2010, Trends in Endocrinology & Metabolism.

[57]  Michael R Dores,et al.  Signal transduction by protease‐activated receptors , 2010, British journal of pharmacology.

[58]  P. Vanhoutte,et al.  The thromboxane/endoperoxide receptor (TP): the common villain. , 2010, Journal of cardiovascular pharmacology.

[59]  G. E. Callander,et al.  Relaxin family peptide systems and the central nervous system , 2010, Cellular and Molecular Life Sciences.

[60]  R. Quirion,et al.  A possible role of neuropeptide Y in depression and stress , 2010, Brain Research.

[61]  K. Commons Neuronal pathways linking substance P to drug addiction and stress , 2010, Brain Research.

[62]  Willem van der Westhuizen,et al.  Power station pump selection: part 2 , 2010 .

[63]  K. Jacobson,et al.  Adenosine A3 Receptors in Muscle Protection , 2010 .

[64]  Ross A. D. Bathgate,et al.  Cardiovascular effects of relaxin: from basic science to clinical therapy , 2010, Nature Reviews Cardiology.

[65]  I. Depoortere,et al.  Motilin and ghrelin as prokinetic drug targets. , 2009, Pharmacology & therapeutics.

[66]  T. Sotnikova,et al.  Trace Amine-Associated Receptors as Emerging Therapeutic Targets , 2009, Molecular Pharmacology.

[67]  S. Douglas,et al.  Neurokinin 1 receptor isoforms and the control of innate immunity. , 2009, Trends in immunology.

[68]  Takao Shimizu,et al.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.

[69]  V. Georgiev,et al.  Drug Development Research , 2009, National Institute of Allergy and Infectious Diseases, NIH.

[70]  M. Zatelli,et al.  The significance of new somatostatin analogs as therapeutic agents. , 2009, Current opinion in investigational drugs.

[71]  R. Quirion,et al.  International Union of Pharmacology. LXIX. Status of the Calcitonin Gene-Related Peptide Subtype 2 Receptor , 2008, Pharmacological Reviews.

[72]  K. Dezaki,et al.  Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. , 2008, Pharmacology & therapeutics.

[73]  S. O'Sullivan,et al.  Cannabinoids go nuclear: evidence for activation of peroxisome proliferator‐activated receptors , 2007, British journal of pharmacology.

[74]  K. Sullivan A royal charter , 2007 .

[75]  M. Glass,et al.  Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences , 2007, British journal of pharmacology.

[76]  Stephen P. H. Alexander,et al.  The complications of promiscuity: endocannabinoid action and metabolism , 2007, British journal of pharmacology.

[77]  C. Delporte,et al.  Influence of ghrelin on food intake and energy homeostasis , 2007, Current opinion in clinical nutrition and metabolic care.

[78]  S. Petrosino,et al.  Endocannabinoids and the regulation of their levels in health and disease , 2007, Current opinion in lipidology.

[79]  W. Froestl,et al.  Chemistry of GABAB Modulators , 2007 .

[80]  G. Chiellini,et al.  Trace amine‐associated receptors and their ligands , 2006, British journal of pharmacology.

[81]  R. Ivell,et al.  International Union of Pharmacology LVII: Recommendations for the Nomenclature of Receptors for Relaxin Family Peptides , 2006, Pharmacological Reviews.

[82]  Cheryl L. Morse,et al.  Automated radiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptors with PET , 2006 .

[83]  T. Bártfai,et al.  M871—A Novel Peptide Antagonist Selectively Recognizing the Galanin Receptor Type 2 , 2006, International Journal of Peptide Research and Therapeutics.

[84]  R. Neubig,et al.  International Union of Pharmacology. LVI. Ghrelin Receptor Nomenclature, Distribution, and Function , 2005, Pharmacological Reviews.

[85]  Richard R. Neubig,et al.  International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List , 2005, Pharmacological Reviews.

[86]  D. Millar Taking the Initiative , 2005 .

[87]  J. Kukkonen,et al.  Intracellular Signal Pathways Utilized by the Hypocretin/Orexin Receptors , 2005 .

[88]  F. Marceau,et al.  Bradykinin receptor ligands: therapeutic perspectives , 2004, Nature Reviews Drug Discovery.

[89]  L. Clozel Combinatorial consequences of Arthur's conjectures and the Burger-Sarnak method , 2004 .

[90]  K. Payza Binding and Activity of Opioid Ligands at the Cloned Human Delta, Mu, and Kappa Receptors , 2003 .

[91]  Patrick M. Sexton,et al.  International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors , 2002, Pharmacological Reviews.

[92]  Barry Anderson,et al.  A guide to modern science : science and technology in today's world / Barry Anderson ... [et al.] ; consultant editor, Wilson Da Silva. , 2002 .

[93]  P. Seeman Antipsychotic drugs, dopamine receptors, and schizophrenia , 2001, Clinical Neuroscience Research.

[94]  R. Breton Les langues non-tatiques dEurope: relev gopolitique et dmographique , 2001 .

[95]  G. Guillon,et al.  Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. , 2000, Kidney international.

[96]  G. Camussi,et al.  Role of platelet-activating factor in cardiovascular pathophysiology. , 2000, Physiological reviews.

[97]  S. Ishii,et al.  Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. , 2000, Progress in lipid research.

[98]  K. Jacobson,et al.  1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.

[99]  D. Pruneau,et al.  Pharmacological characterization of the bradykinin B2 receptor: inter‐species variability and dissociation between binding and functional responses , 1999, British journal of pharmacology.

[100]  S. Rawlings,et al.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. , 1998, Pharmacological reviews.

[101]  H Herzog,et al.  XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. , 1998, Pharmacological reviews.

[102]  J. F. Brown,et al.  Role of mast cells, neutrophils and nitric oxide in endotoxin‐induced damage to the neonatal rat colon , 1998, British journal of pharmacology.

[103]  P. Jj Le jaune d'oeuf, une cible pour les salmonelles , 1997 .

[104]  G. Mcallister,et al.  5-HT1E and 5-HT1F receptors , 1997 .

[105]  P. Braquet,et al.  Platelet-activating factor antagonists , 1995, Clinical Reviews in Allergy.

[106]  J. Macor,et al.  Biochemical and behavioral studies of the 5‐HT1B receptor agonist, CP‐94,253 , 1992 .

[107]  F. Snyder Platelet-Activating Factor and Related Lipid Mediators , 1987, Springer US.

[108]  B Fisher,et al.  Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. , 1985, The New England journal of medicine.

[109]  J. Reubi,et al.  Somatostatin Receptors , 1997, Trends in Endocrinology & Metabolism.

[110]  H. Maeno,et al.  Dopamine Receptors , 2018 .